31 March 2015 - - Canadian biopharmaceutical company InMed Pharmaceuticals Inc. (CSE: IN) (OTCQB: IMLFF) has appointed Paul C. Anderson, Ph.D., to its scientific advisory board, the company said on Tuesday. Anderson is a pharma industry veteran who brings significant drug discovery and development expertise to InMed. He is a synthetic organic chemist by training with more than 30 years of experience in pharmaceutical research and development. Following postdoctoral studies in bioorganic chemistry at the University of Cambridge, Dr. Anderson began his career in the pharmaceutical industry at Merck Frosst Canada Inc. He subsequently joined Boehringer Ingelheim and in more than 20 years with the company, held positions of increasing responsibility in the research organization including more than 12 years as head of the Boehringer Ingelheim research centers in Canada and in the United States. While in Canada, Anderson and his team introduced several anti-viral drugs into pre-clinical and clinical development, including the first HCV protease inhibitor to be tested in humans. As head of research for Boehringer Ingelheim in the United States, Dr. Anderson and his team carried out research on autoimmune and cardiovascular diseases, advancing several compounds into pre-clinical development. He received his Ph.D. in organic chemistry at the University of Alberta. Anderson is also a consultant for the National Institutes of Health Blueprint Neurotherapeutics Network. In addition, InMed appointed Dr. Sazzad Hossain to its board of directors. Hossain is the current chief scientific officer of InMed and a co-founder of the company. He developed the "IDP" drug discovery platform and is leading all Rand D activities of InMed Pharmaceuticals. InMed is a clinical stage biopharmaceutical company that specialises in developing cannabis based therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.